Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_D51407044D20
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
UNIL/CHUV
Title
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
Journal
The Lancet. Oncology
Author(s)
da Silva I.P., Ahmed T., Reijers ILM, Warner A.B., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Zimmer L., Trojaniello C., Klein O., Gerard C.L., Michielin O., Haydon A., Ascierto P.A., Carlino M.S., Lebbe C., Lorigan P., Johnson D.B., Sandhu S., Lo S.N., Menzies A.M., Long G.V.
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Publication state
Published
Issued date
08/2021
Peer-reviewed
Oui
Volume
22
Number
8
Pages
e343-e344
Language
english
Notes
Publication types: Letter ; Comment
Publication Status: ppublish
Keywords
Humans, Ipilimumab/adverse effects, Melanoma/drug therapy, Nivolumab/adverse effects
OAI-PMH
oai:serval.unil.ch:BIB_D51407044D20
DOI
10.1016/S1470-2045(21)00419-8
Pubmed
34339647
Web of science
000684199600002
Create date
06/08/2021 10:38
Last modification date
12/10/2021 5:40
Usage data